Volume 13 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Niu Yishan, Zeng Qiang. Predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 49-54. doi: 10.3969/j.issn.1674-7445.2022.01.008
Citation: Niu Yishan, Zeng Qiang. Predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 49-54. doi: 10.3969/j.issn.1674-7445.2022.01.008

Predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma

doi: 10.3969/j.issn.1674-7445.2022.01.008
More Information
  • Corresponding author: Zeng Qiang, E-mail: zengqiang457@qq.com
  • Received Date: 2021-08-24
    Available Online: 2022-01-12
  • Publish Date: 2022-01-15
  • Tumor recurrence is the main issue that affects the long-term survival of recipients after liver transplantation for hepatocellular carcinoma. Accurate preoperative evaluation and proper selection of transplant recipients are the key factors affecting the long-term prognosis of recipients undergoing liver transplantation for hepatocellular carcinoma. Neutrophil, lymphocyte, C-reactive protein, platelet and fibrinogen (FIB) are major biomarkers that indicate inflammatory response of the host. Multiple studies have found that these biomarkers may not only represent the inflammatory response, but also could be integrated to predict tumor recurrence and long-term survival rate of the recipients following liver transplantation for hepatocellular carcinoma. These biomarkers mainly consist of neutrophil-to-lymphocyte ratio (NLR), Glasgow prognostic score (GPS), FIB, platelet-to-lymphocyte ratio (PLR) and prognostic nutritional index (PNI), etc. In this article, research progresses on predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma were reviewed.

     

  • loading
  • [1]
    CITORES MJ, LUCENA JL, DE LA FUENTE S, et al. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation[J]. World J Hepatol, 2019, 11(1): 50-64. DOI: 10.4254/wjh.v11.i1.50.
    [2]
    SIMSEK C, KIM A, MA M, et al. Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series[J]. Hepatoma Res, 2020, 6: 11. DOI: 10.20517/2394-5079.2019.51.
    [3]
    SALEH M, KHALIL M, ABDELLATEIF MS, et al. Role of matrix metalloproteinase MMP-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP-1) in the clinical progression of pediatric acute lymphoblastic leukemia[J]. Hematology, 2021, 26(1): 758-768. DOI: 10.1080/16078454.2021.1978763.
    [4]
    MIETHE C, TORRES L, ZAMORA M, et al. Inhibition of PI3K/Akt and ERK signaling decreases visfatin-induced invasion in liver cancer cells[J]. Horm Mol Biol Clin Investig, 2021, 42(4): 357-366. DOI: 10.1515/hmbci-2021-0011.
    [5]
    WAIGEL S, RENDON BE, LAMONT G, et al. MIF inhibition reverts the gene expression profile of human melanoma cell line-induced MDSCs to normal monocytes[J]. Genom Data, 2016, 7: 240-242. DOI: 10.1016/j.gdata.2015.12.025.
    [6]
    NYLEC M, DERBISZ K, CHRZĄSZCZ P, et al. Preoperative neutrophil-to-lymphocyte ratio as an independent predictor of 1-year graft loss and mortality after orthotopic liver transplantation[J]. Transplant Proc, 2020, 52(8): 2472-2476. DOI: 10.1016/j.transproceed.2020.03.036.
    [7]
    NAGAI S, YOSHIDA A, KOHNO K, et al. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation[J]. Hepatology, 2014, 59(1): 35-45. DOI: 10.1002/hep.26536.
    [8]
    FIGIEL W, GRĄT M, NIEWIŃSKI G, et al. Applicability of common inflammatory markers in diagnosing infections in early period after liver transplantation in intensive care setting[J]. Sci Rep, 2020, 10(1): 3918. DOI: 10.1038/s41598-020-60936-0.
    [9]
    HARIMOTO N, YOSHIZUMI T, SHIMAGAKI T, et al. Inflammation-based prognostic score in patients with living donor liver transplantation for hepatocellular carcinoma[J]. Anticancer Res, 2016, 36(10): 5537-5542. DOI: 10.21873/anticanres.11137.
    [10]
    HARIMOTO N, SHIRABE K, NAKAGAWARA H, et al. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio[J]. Transplantation, 2013, 96(11): 1008-1012. DOI: 10.1097/TP.0b013e3182a53f2b.
    [11]
    WANG GY, YANG Y, LI H, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J]. PLoS One, 2011, 6(9): e25295. DOI: 10.1371/journal.pone.0025295.
    [12]
    REN A, LI Z, ZHANG X, et al. Inflammation-based prognostic scores in patients with hepatitis B virus-related hepatocellular carcinoma after liver transplantation[J]. J Hepatocell Carcinoma, 2020, 7: 101-106. DOI: 10.2147/JHC.S259992.
    [13]
    MEISCHL T, RASOUL-ROCKENSCHAUB S, GYÖRI G, et al. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation[J]. PLoS One, 2019, 14(5): e0216677. DOI: 10.1371/journal.pone.0216677.
    [14]
    ABE T, TASHIRO H, HATTORI M, et al. Prediction of long-term survival by using the Glasgow prognostic score in patients with hepatocellular carcinoma after liver transplantation[J]. Hepatol Res, 2016, 46(7): 622-633. DOI: 10.1111/hepr.12597.
    [15]
    KALTENBORN A, SCHREM H, REICHERT B, et al. The Glasgow prognostic score and its variants predict mortality in living donor but not in deceased donor liver transplantation for hepatocellular carcinoma: a double-center validation study[J]. Hepatol Res, 2017, 47(8): 783-792. DOI: 10.1111/hepr.12818.
    [16]
    LI Y, LI Z, DENG K, et al. Fibrinogen/lymphocyte count ratio can be used as a new indicator of prognosis in patients with hepatocellular carcinoma after radical resection[J]. Cancer Manag Res, 2020, 12: 9057-9066. DOI: 10.2147/CMAR.S266653.
    [17]
    PAVLOVIC N, RANI B, GERWINS P, et al. Platelets as key factors in hepatocellular carcinoma[J]. Cancers (Basel), 2019, 11(7): 1022. DOI: 10.3390/cancers11071022.
    [18]
    PALACIOS-ACEDO AL, MÈGE D, CRESCENCE L, et al. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy[J]. Front Immunol, 2019, 10: 1805. DOI: 10.3389/fimmu.2019.01805.
    [19]
    DAI T, PENG L, LIN G, et al. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma[J]. J Gastrointest Oncol, 2019, 10(6): 1049-1063. DOI: 10.21037/jgo.2019.09.11.
    [20]
    WANG GY, JIANG N, YI HM, et al. Pretransplant elevated plasma fibrinogen level is a novel prognostic predictor for hepatocellular carcinoma recurrence and patient survival following liver transplantation[J]. Ann Transplant, 2016, 21: 125-130. DOI: 10.12659/aot.895416.
    [21]
    HUANG G, JIANG H, LIN Y, et al. Prognostic value of plasma fibrinogen in hepatocellular carcinoma: a Meta-analysis[J]. Cancer Manag Res, 2018, 10: 5027-5041. DOI: 10.2147/CMAR.S175780.
    [22]
    FU SJ, JI F, HAN M, et al. Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation[J]. Oncotarget, 2017, 8(3): 4301-4312. DOI: 10.18632/oncotarget.13804.
    [23]
    AUGUSTINE TN. The aegis: platelets as biomarkers of tumor progression[J]. Biomark Med, 2020, 14(7): 573-585. DOI: 10.2217/bmm-2019-0514.
    [24]
    BRAUN A, ANDERS HJ, GUDERMANN T, et al. Platelet-cancer interplay: molecular mechanisms and new therapeutic avenues[J]. Front Oncol, 2021, 11: 665534. DOI: 10.3389/fonc.2021.665534.
    [25]
    HAN S. Possible roles of platelets in liver transplantation: regeneration and cancer recurrence[J]. Anesth Pain Med (Seoul), 2021, 16(3): 225-231. DOI: 10.17085/apm.21063.
    [26]
    HAN S, LEE S, YANG JD, et al. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation[J]. Liver Transpl, 2018, 24(1): 44-55. DOI: 10.1002/lt.24961.
    [27]
    XIA W, KE Q, WANG Y, et al. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation[J]. World J Surg Oncol, 2015, 13: 60. DOI: 10.1186/s12957-015-0472-2.
    [28]
    LIU Y, SHI M, CHEN S, et al. Intermediate stage hepatocellular carcinoma: comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization[J]. J Cancer Res Ther, 2021, 17(3): 740-748. DOI: 10.4103/jcrt.jcrt_29_21.
    [29]
    WANG D, BAI N, HU X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC[J]. PeerJ, 2019, 7: e7132. DOI: 10.7717/peerj.7132.
    [30]
    LAI Q, MELANDRO F, LARGHI LAUREIRO Z, et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: a systematic review and Meta-analysis[J]. World J Gastroenterol, 2018, 24(15): 1658-1665. DOI: 10.3748/wjg.v24.i15.1658.
    [31]
    ISMAEL MN, FORDE J, MILLA E, et al. Utility of inflammatory markers in predicting hepatocellular carcinoma survival after liver transplantation[J]. Biomed Res Int, 2019: 7284040. DOI: 10.1155/2019/7284040.
    [32]
    XIA W, KE Q, GUO H, et al. Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio[J]. BMC Cancer, 2017, 17(1): 14. DOI: 10.1186/s12885-016-3028-0.
    [33]
    WANG Z, WANG J, WANG P. The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: a Meta-analysis of observational studies[J]. PLoS One, 2018, 13(10): e0202987. DOI: 10.1371/journal.pone.0202987.
    [34]
    TANEMURA A, MIZUNO S, HAYASAKI A, et al. Onodera's prognostic nutritional index is a strong prognostic indicator for patients with hepatocellular carcinoma after initial hepatectomy, especially patients with preserved liver function[J]. BMC Surg, 2020, 20(1): 261. DOI: 10.1186/s12893-020-00917-2.
    [35]
    JI F, LIANG Y, FU S, et al. Prognostic value of combined preoperative prognostic nutritional index and body mass index in HCC after hepatectomy[J]. HPB (Oxford), 2017, 19(8): 695-705. DOI: 10.1016/j.hpb.2017.04.008.
    [36]
    MIN JY, WOO A, CHAE MS, et al. Predictive impact of modified-prognostic nutritional index for acute kidney injury within 1-week after living donor liver transplantation[J]. Int J Med Sci, 2020, 17(1): 82-88. DOI: 10.7150/ijms.39014.
    [37]
    PRAVISANI R, MOCCHEGIANI F, ISOLA M, et al. Postoperative trends and prognostic values of inflammatory and nutritional biomarkers after liver transplantation for hepatocellular carcinoma[J]. Cancers (Basel), 2021, 13(3): 513. DOI: 10.3390/cancers13030513.
    [38]
    LIU C, LI L, LU WS, et al. Neutrophil-lymphocyte ratio plus prognostic nutritional index predicts the outcomes of patients with unresectable hepatocellular carcinoma after transarterial chemoembolization[J]. Sci Rep, 2017, 7(1): 13873. DOI: 10.1038/s41598-017-13239-w.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Article Metrics

    Article views (533) PDF downloads(128) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return